МАКНАМАРА Тим (US),ЧЭНДЛЕР Саймон П. (US),КИДА Тецуо (JP)
申请号：
RU2010138799/15
公开号：
RU2010138799A
申请日:
2009.02.19
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A method of increasing the interval between intravitreal injections in a patient receiving treatment for retinal disease with a VEGF inhibitor to maximize visual acuity, where the method includes the step of administering to the patient in need of such treatment an effective amount of an adjuvant containing one or more ophthalmic NSAIDs. ! 2. The method according to claim 1, wherein the retinal disease is wet AMD, diabetic retinopathy, diabetic macular edema, occlusion of the central retinal vein and occlusion of the central retinal vein branch. ! 3. The method according to claim 1, in which the NSAID is bromfenac, diclofenac, flurbiprofen, ketorolac, nepafenac, amfenac or indomethacin. ! 4. The method according to claim 3, in which the NSAID is bromfenac. ! 5. The method according to claim 1, in which the VEGF inhibitor is bevacizumab, ranibizumab or pegaptanib. ! 6. The method according to claim 1, in which the NSAIDs are applied topically to the eye. ! 7. The method of claim 1, wherein the NSAIDs are applied before, during, or after administration of the VEGF inhibitor. ! 8. The method according to claim 1, in which the interval between intravitreal injections is increased by one or several months. ! 9. A method of reducing the number of intravitreal injections in a patient receiving treatment for a retinal disease with a VEGF inhibitor to maximize visual acuity, where the method includes the step of administering to a patient in need of such treatment an effective amount of an adjuvant containing one or more ophthalmic NSAIDs. ! 10. The method according to claim 9, in which the disease of the retina is wet AMD, diabetic retinopathy, diabetic macular edema, occlusion of the central retinal vein and occlusion of the branch of the central retinal vein. ! 11. The method according to claim 9, in which1. Способ увеличения интервала между интравитреальными инъекциями у пациента, получающего лечение от заболевания сетчатки ингибитором VEGF, для максимизации остроты з
